

Supporting Information

Photoswitchable azobenzene-appended iridium(III) complexes

J. Pérez-Miqueo,^a A. Altube,^b E. García-Lecina,^b A. Tron,^c N.
McClenaghan,^c Z. Freixa.*^{a,d}

^aDepartment of Applied Chemistry, Faculty of Chemistry, University of the Basque Country (UPV-EHU), San Sebastián, Spain. E-mail: Zoraida_freixa@ehu.eus

^bSurfaces Division, IK4-CIDETEC, San Sebastián, Spain.

^cInstitut des Sciences Moléculaires, CNRS UMR 5255, University of Bordeaux, 33405 Talence, France .

^dIKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

Synthesis, characterization and UV/Vis photoisomerization studies of new compounds.	3–55
Compound d (Fig. S1–Fig. S4)	3
Ligand 1 (Fig. S5–Fig. S10)	6
(6-Phenyl-3-pyridyl)-boronic acid (Fig. S11–Fig. S14)	10
Ligand 2 (Fig. S15–Fig. S20)	13
Ligand 3 (Fig. S21–Fig. S27)	17
Ligand 5 (Fig. S28–Fig. S34)	21
[Ir(ppyBr) ₂ Cl] ₂	25
[Ir(ppyBr) ₂ (acac)] (Fig. S35–Fig. S39)	26
[Ir(5) ₂ (acac)] (Fig. S40–Fig. S46)	29
[Ir(ppy) ₂ (1)] (Fig. S47–Fig. S53)	33
[Ir(ppy) ₂ (2)] (Fig. S54–Fig. S59)	38
[Ir(ppy) ₂ (3)] (Fig. S60–Fig. S66)	42
[Ir(Fppy) ₂ (1)] (Fig. S67–Fig. S73)	46
[Ir(Brppy) ₂ (1)] (Fig. S74–Fig. S80)	51
[Ir(4) ₂ (1)] (Fig. S81)	55
¹H-NMR photoisomerization studies	56–61
Fig. S82. ¹ H-NMR spectra of ligand 1	56
Fig. S82. ¹ H-NMR spectra of ligand 2	56
Fig. S82. ¹ H-NMR spectra of ligand 3	57
Fig. S82. ¹ H-NMR spectra of ligand 4	57
Fig. S82. ¹ H-NMR spectra of ligand 5	58
Fig. S82. ¹ H-NMR spectra of [Ir(4) ₂ (acac)]	58
Fig. S82. ¹ H-NMR spectra of [Ir(5) ₂ (acac)]	59
Fig. S82. ¹ H-NMR spectra of [Ir(ppy) ₂ (2)]	59
Fig. S82. ¹ H-NMR spectra of [Ir(ppy) ₂ (1)]	60
Fig. S82. ¹ H-NMR spectra of [Ir(Fppy) ₂ (1)]	60
Fig. S82. ¹ H-NMR spectra of [Ir(Brppy) ₂ (1)]	61
Fig. S82. ¹ H-NMR spectra of [Ir(ppy) ₂ (3)]	61
Cyclic-voltammograms	62–64
Fig. S94. Cyclic voltammograms of [Ir(ppy) ₂ (1)], [Ir(Fppy) ₂ (1)] and [Ir(Brppy) ₂ (1)]	62
Fig. S95. Cyclic voltammograms of [Ir(ppy) ₂ (4)] and [Ir(Fppy) ₂ (4)]	62
Fig. S96. Cyclic voltammograms of [Ir(4) ₂ (acac)] and [Ir(5) ₂ (acac)]	63
Fig. S97. Cyclic voltammograms of [Ir(ppy) ₂ (2)]	63
Fig. S98. Cyclic voltammograms of [Ir(ppy) ₂ (3)]	64
NMR simulation	64
Fig. S99. ¹ H-NMR spectra of compounds [Ir(Fppy) ₂ (1)] and [Ir(Brppy) ₂ (1)]	64

Compound d. Synthesis and characterization.**SYNTHESIS**

4-(Phenylazo)phenol (2.00 g, 10.1 mmol), (4-bromomethylphenyl)boronic acid pinacol ester (3.58 g, 12.1 mmol) and NaOH (0.80 g, 20.0 mmol) were dissolved in 170 mL of a degassed mixture of CH₃CN/CH₂Cl₂ (20:3, v/v). The solution was then stirred and refluxed (95 °C) for 2 days under N₂. The solution was cooled to room temperature and gravity-filtered to remove NaBr. After concentrating *in vacuo*, the resulting solid was purified by column chromatography (silica, CH₂Cl₂, R_f = 0.7). The title compound was obtained as an orange solid (2.70 g, 65%).

Elemental Analysis: calculated for C₂₅H₂₇F₃BN₂O₃: C, 72.48; H, 6.57; N, 6.76. Found: C, 72.52; H, 6.73; N, 6.41.

Exact mass (MALDI) - m/z: 415.2186 for [M + H]⁺.

¹H NMR (300 MHz, CDCl₃): δ 7.97-7.88 (m, 6H), 7.57-7.47 (m, 5H), 7.12 (d, *J* = 9.0, 2H, C₆H₄ (C₁₂H₉N₂)), 5.22 (s, 2H, CH₂), 1.40 (s, 12H, CH₃).

¹³C NMR (75 MHz, CDCl₃): δ 161.12 (1C, C_{quat.}), 152.75 (1C, C_{quat.}), 147.15 (1C, C_{quat.}), 139.54 (1C, C_{quat.}), 135.10 (2C, CH), 130.35 (1C, CH, C₆H₄ (C₁₂H₉N₂)), 129.00 (2C, CH), 126.52 (2C, CH), 124.72 (2C, CH), 122.55 (2C, CH), 115.13 (2C, CH), 83.84 (2C, C_{quat.}), 70.14 (1C, CH₂), 24.85 (4C, CH₃), (C-B not seen)




Fig. S1. ¹H NMR spectrum of compound **d** in CDCl₃, 300 MHz.

Supporting Information




Fig. S2. ¹³C NMR spectrum of compound **d** in CDCl₃, 75 MHz.




Fig. S3. HSQC spectrum of compound **d** in CDCl₃.




Fig. S4. COSY spectrum of compound **d** in CDCl₃.

Ligand 1. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

The compound **d** (2.65 g, 6.3 mmol) was dissolved in 38 mL of degassed THF. To this mixture, 2-bromopyridine (1.11 g, 0.67 mL, 7.0 mmol), Pd(PPh₃)₄ (2 mol%, 0.15 g, 1.3 mmol), and Na₂CO₃ (1 M aq., 19 mL) were added successively under nitrogen, and heated overnight at 80 °C. The reaction was cooled to room temperature and 60 mL of water was added. The resulting mixture was extracted with ethyl acetate (5 × 10 mL), dried (MgSO₄), filtered and evaporated *in vacuo*. The resulting solid was washed with ethanol and dried *in vacuo*; the product was obtained as an orange powder (2.22 g, 95%).

Elemental Analysis: calculated for C₂₄H₁₉N₃O · 0.9CH₂Cl₂: C, 67.51; H, 4.74; N, 9.48. Found: C, 67.51; H, 4.69; N, 8.98.

Exact mass (EI) - m/z: 366.1603 for [M + H]⁺.

¹H NMR (300 MHz, CDCl₃): δ 8.74 (d, *J* = 4.6, 1H, C₅H₄N), 8.08 (d, *J* = 8.3, 2H, C₆H₄ (C₁₁H₈N)), 7.96 (d, *J* = 9.0, 2H, C₆H₄ (C₁₂H₉N₂)), 7.93 – 7.90 (m, 2H, C₆H₅), 7.82 – 7.78 (m, 2H, C₅H₄N), 7.60 (d, *J* = 8.4, 2H, C₆H₄ (C₁₁H₈N)), 7.57 – 7.44 (m, 3H, C₆H₅), 7.29 – 7.26 (m, 1H, C₅H₄N), 7.15 (d, *J* = 9.0, 2H, C₆H₄ (C₁₂H₉N₂)), 5.26 (s, 2H, CH₂).

¹³C NMR (75 MHz, CDCl₃): δ 161.10 (1C, C_{quat.}), 156.96 (1C, C_{quat.}), 152.71 (1C, C_{quat.}), 149.62 (1C, CH, C₅H₄N), 147.15 (1C, C_{quat.}), 139.18 (1C, C_{quat.}), 137.22 (1C, C_{quat.}), 136.85 (1C, CH, C₅H₄N), 130.36 (1C, CH, C₆H₅), 128.98 (2C, CH, C₆H₅), 127.76 (2C, CH, C₆H₄ (C₁₁H₈N)), 127.20 (2C, CH, C₆H₄ (C₁₁H₈N)), 124.72 (2C, CH, C₆H₄ (C₁₂H₉N₂)), 122.52 (2C, CH, C₆H₅), 122.24 (1C, CH, C₅H₄N), 120.63 (1C, CH, C₅H₄N), 115.13 (2C, CH, C₆H₄ (C₁₂H₉N₂)), 69.92 (1C, CH₂).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 345 (1.7 · 10⁴), 444 (0.6 · 10³).




Fig. S5. ¹H NMR spectrum of ligand **1** in CDCl₃, 300 MHz.

Supporting Information




Fig. S6. ^{13}C NMR spectrum of ligand **1** in CDCl_3 , 75 MHz.




Fig. S7. HSQC NMR spectrum of ligand **1** in CDCl_3 .




Fig. S8. COSY NMR spectrum of ligand **1** in CDCl_3 .




Fig. S9. UV/Vis spectra of ligand **1** in CH_3CN . Before (pink line) and after (blue line) irradiation at 347nm, $2.50 \cdot 10^{-5}$ M.




Fig. S10. *Cis* to *trans* thermal isomerization kinetics of ligand **1**. All k values were calculated from the first-order plots of absorption change of the band 345 nm at 328 K in CH_3CN after irradiation at 347 nm ($2.50 \cdot 10^{-5}\text{M}$). *Cis* to *trans* thermal isomerization of this complex is slow, and the A_{∞} (1.200) value obtained in the kinetic measure does not correspond to A_{∞} value (1.256) obtained as maximum of absorbance before the photoisomerization. We have used $A_{\infty} = 1.256$ as maximum of absorbance corresponding to *trans* isomer. k (s^{-1}) = $0.9 \cdot 10^{-4}$. Half-life (s) = 7600.

(6-Phenyl-3-pyridyl)-boronic acid. Synthesis and characterization.**SYNTHESIS**

5-Bromo-2-phenylpyridine (2.00 g, 8.6 mmol) was dissolved in 13 mL of distilled toluene and 4 mL of distilled THF. Triisopropyl borate (2.30 mL, 10.2 mmol) and n-BuLi (1.6 M in hexane, 6.40 mL, 10.2 mmol) were added at -40 °C under N₂ atmosphere, and the reaction mixture was stirred for 1 hour at this temperature. The reaction mixture was allowed to warm up to -20 °C and 10 mL of HCl_(aq.) (2 M) were added. When the reaction mixture reached r.t., it was quenched with water and treated with a NaOH aqueous solution (5 M) until a neutral pH was reached. The mixture was saturated with NaCl and it was extracted with THF (3 × 50 mL). The combined organic layers were dried over MgSO₄. The solvent was removed *in vacuo* and the residue was washed with ether and dichloromethane. The product was obtained as a white solid (1.60 g, 95%).

Elemental Analysis: calculated for C₁₁H₁₀BNO₂ · 1.75CH₂Cl₂: C, 44.05; H, 3.91; N, 4.03. Found: C, 43.80; H, 3.47; N, 4.42.

Exact mass (EI) - m/z: 200.0884 for [M + H]⁺.

¹H NMR (300 MHz, MeOD): δ 8.82 (s, 1H, C₅H₃N), 8.38 (d, *J* = 7.9, 1H, C₅H₃N), 8.03 – 7.95 (m, 3H), 7.60 – 7.55 (m, 3H, C₆H₅).

¹³C NMR (75 MHz, MeOD): δ 157.00 (1C, C_{quat.}), 152.02 (1C, CH, C₅H₃N), 147.08 (1C, CH, C₅H₃N), 137.99 (1C, C_{quat.}), 131.23 (1C, CH, C₆H₅), 130.20 (2C, CH, C₆H₅), 128.73 (2C, CH, C₆H₅), 122.88 (1C, CH, C₅H₃N), (C-B not seen).




Fig. S11. ¹H NMR spectrum of (6-phenyl-3-pyridyl)-boronic acid in MeOD, 300 MHz.



Fig. S12. ^{13}C NMR spectrum of (6-phenyl-3-pyridyl)-boronic acid in MeOD, 75 MHz.

Fig. S13. HSQC NMR spectrum of (6-phenyl-3-pyridyl)-boronic acid in MeOD.




Fig. S14. COSY NMR spectrum of (6-phenyl-3-pyridyl)-boronic acid in MeOD.

Ligand 2. Synthesis, characterization and photoisomerization studies.**SYNTHESIS.**

(6-Phenyl-3-pyridyl)-boronic acid (300 mg, 1.50 mmol) and Pd(PPh₃)₄ (3 mol%, 35 mg, 0.03 mmol) were dissolved in 10 mL of DME. The mixture was stirred under N₂ at 50 °C for 10 min. To this solution, 4-(phenylazo)benzyl bromide (280 mg, 1.00 mmol) dissolved in 3 mL of DME/ethanol (2:1, v/v) and Na₂CO₃ (2 M aq., 2.0 mL) were added successively under nitrogen, and heated overnight at 110 °C with continuous stirring. The reaction was cooled to room temperature and 50 mL of water were added. The resulting mixture was extracted with ethyl acetate (5 × 10 mL), dried (MgSO₄), filtered and the solvent removed *in vacuo*. The resulting solid was purified on by column chromatography (silica, CH₂Cl₂, R_f = 0.4); the product was obtained as a red crystalline solid (140 mg, 40%).

Elemental Analysis: calculated for C₂₄H₁₉N₃: C, 82.49; H, 5.48; N, 12.03. Found: C, 82.63; H, 5.22; N, 11.94.

Exact mass (MALDI) - m/z: 350.1646 for [M + H]⁺.

¹H NMR (300 MHz, CDCl₃): δ 8.66 (d, *J* = 1.8, 1H, C₅H₃N), 8.03 (d, *J* = 6.9, 2H), 7.98 – 7.91 (m, 4H), 7.71 (dd, *J* = 8.1, 0.4, 1H, C₅H₃N), 7.61 – 7.44 (m, 7H), 7.40 (d, *J* = 8.5, 2H, C₆H₄), 4.14 (s, 2H, CH₂).

¹³C NMR (75 MHz, CDCl₃): δ 155.68 (1C, C_{quat.}), 152.64 (1C, C_{quat.}), 151.37 (1C, C_{quat.}), 149.95 (1C, CH, C₅H₃N), 143.11 (1C, C_{quat.}), 139.10 (1C, C_{quat.}), 137.13 (1C, CH), 134.30 (1C, C_{quat.}), 130.90 (1C, CH), 129.57 (2C, CH), 129.05 (2C, CH), 128.80 (1C, CH), 128.71 (2C, CH), 126.75 (2C, CH), 123.21 (2C, CH), 122.78 (2C, CH), 120.35 (1C, CH, C₅H₃N), 38.57 (1C, CH₂).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 326 (2.2 · 10⁴), 435 (0.9 · 10³).




Fig. S15. ¹H NMR spectrum of ligand 2 in CDCl₃, 300 MHz.

Supporting Information




Fig. S16. ^{13}C APT NMR spectrum of ligand **2** in CDCl_3 , 75 MHz.




Fig. S17. HSQC NMR spectrum of ligand **2** in CDCl_3 .




Fig. S18. COSY NMR spectrum of ligand **2** in CDCl_3 .




Fig. S19. UV/Vis spectra of ligand **2** in CH_3CN . Before (pink line) and after (blue line) irradiation at 326 nm, $2.50 \cdot 10^{-5}$ M.




Fig. S20. *Cis* to *trans* thermal isomerization kinetics of ligand **2**. All k values were calculated from the first-order plots of absorption change of the band 326 nm at 328 K in CH₃CN after irradiation at 327 nm ($2.50 \cdot 10^{-5}$ M). *Cis* to *trans* thermal isomerization of this complex is slow, and the A_{∞} (1.339) value obtained in the kinetic measure does not correspond to A_{∞} value (1.616) obtained as maximum of absorbance before the photoisomerization. We have used $A_{\infty} = 1.616$ as maximum of absorbance corresponding to *trans* isomer. k (s⁻¹) = $0.4 \cdot 10^{-4}$. Half-life (s) = 16000.

Ligand 3. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

4-(phenylazo)iodobenzene (0.77 g, 2.5 mmol) was dissolved in 10 mL of DMSO. To this mixture, acetylacetone (0.75 g, 0.77 mL, 7.50 mmol), K₂CO₃ (1.38 g, 10.0 mmol), CuI (0.05 g, 0.3 mmol) and *L*-proline (0.06 g, 0.5 mmol) were added successively under nitrogen, and heated at 90 °C for 6 h. The reaction mixture was quenched with HCl (1 M, 100 mL) and it was extracted with EtOAc (3 × 25 mL). MgSO₄ was added to the organic fraction, filtered and evaporated *in vacuo*. The resulting solid was purified by column chromatography (silica) eluting with hexane/dichloromethane (5:1, v/v) (R_f = 0.3); the product was obtained as a red crystalline solid (0.25 g, 36%).

Elemental Analysis: calculated for C₁₇H₁₆N₂O₂: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.76; H, 5.52; N, 9.88.

Exact mass (MALDI) - m/z: 281.1277 for [M + H]⁺.

¹H NMR (300 MHz, CDCl₃): δ 16.76 (s, 1H, CH*), 8.01–7.96 (m, 4H), 7.61–7.52 (m, 3H, C₆H₅), 7.40–7.36 (m, 2H, C₆H₄), 1.98 (s, 6H, CH₃).

¹³C NMR (75 MHz, CDCl₃): δ 190.78 (2C, C_{quat}.C=O*), 152.60 (1C, C_{quat}.), 151.87 (1C, C_{quat}.), 139.78 (1C, C_{quat}.), 131.94 (2C, CH, C₆H₄), 131.17 (1C, CH, C₆H₅), 129.12 (2C, CH, C₆H₅), 123.21 (2C, CH), 122.87 (2C, CH), 114.59 (1C, C_{quat}.), 24.20 (2C, CH₃).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 326 (2.0 · 10⁴), 439 (0.8 · 10³).




Fig. S21. ¹H NMR spectrum of ligand **3** in CDCl₃, 300 MHz.

Supporting Information




Fig. S22. ^{13}C APT NMR spectrum of ligand **3** in CDCl_3 , 75 MHz.




Fig. S23. HSQC NMR spectrum of ligand **3** in CDCl_3 .




Fig. S24. COSY NMR spectrum of ligand **3** in CDCl₃.




Fig. S25. UV/Vis spectra of ligand **3** in CH₃CN. Before (pink line) and after (blue line) irradiation at 332 nm, 2.50×10^{-5} M.




Fig. S26. *Cis* to *trans* thermal isomerization kinetics of ligand **3**. Absorption change of the band 326 nm at 328 K in CH₃CN after irradiation at 332 nm ($2.50 \cdot 10^{-5}$ M).




Fig. S27. *Cis* to *trans* thermal isomerization kinetics of ligand **3**. First-order plot. k (s⁻¹) = $1.2 \cdot 10^{-3}$. Half-life (s) = 530.

Ligand 5. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

5-Bromo-2-phenylpyridine (300 mg, 0.130 mmol) was dissolved in 4 mL of degassed THF. To this mixture, 4-(phenylazo)phenyl boronic acid pinacol ester (430 mg, 0.140 mmol), Pd(PPh₃)₄ (2 mol%, 3 mg, 0.003 mmol), Na₂CO₃ (1 M aq., 2 mL) were added successively under nitrogen, and heated overnight at 80 °C with continuous stirring. The reaction mixture was heated overnight at 80 °C with continuous stirring. The reaction was cooled to room temperature and 50 mL of water was added. The resulting mixture was extracted with CH₂Cl₂ (5 × 20 mL), dried over MgSO₄, filtered and evaporated *in vacuo*. The product was washed with dichloromethane (2 mL) and dried *in vacuo*. The product was obtained as an orange powder (380 mg, 88%).

Elemental Analysis: calculated for C₂₃H₁₇N₃ · 0.5CH₂Cl₂: C, 74.70; H, 4.80; N, 11.12. Found: C, 74.83; H, 4.77; N, 11.04.

Exact mass (MALDI) - m/z: 336.1495 for [M+H]⁺.

¹H NMR (300 MHz, CDCl₃): δ 9.06 (d, *J* = 1.9, 1H, C₅H₃N), 8.13 – 8.06 (m, 5H), 8.00 (d, *J* = 8.0, 1.4, 2H), 7.89 (d, *J* = 8.3, 1H, C₅H₃N), 7.85 (d, *J* = 8.5, 2H, C₆H₄), 7.61 – 7.50 (m, 6H).

¹³C NMR (75 MHz, CDCl₃): δ 156.27 (1C, C_{quat.}), 152.28 (1C, C_{quat.}), 151.79 (1C, C_{quat.}), 147.66 (1C, CH, C₅H₃N), 139.64 (1C, C_{quat.}), 138.41 (1C, C_{quat.}), 134.67 (1C, CH, C₅H₃N), 133.54 (1C, C_{quat.}), 130.75 (1C, CH, C₆H₅), 128.74 (1C, CH, C₆H₅), 128.71 (2C, CH, C₆H₅), 128.42 (2C, CH, C₆H₅), 127.20 (2C, CH, C₆H₄), 126.47 (2C, CH), 123.25 (2C, CH), 122.52 (2C, CH, C₆H₅), 119.99 (1C, CH, C₅H₃N).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 347 (3.3 · 10⁴), 436 (1.5 · 10³).




Fig. S28. ¹H NMR spectrum of ligand **5** in CDCl₃, 300 MHz.




Fig. S29. ^{13}C APT NMR spectrum of ligand **5** in CDCl_3 , 75 MHz.




Fig. S30. HSQC NMR spectrum of ligand **5** in CDCl_3 .




Fig. S31. COSY NMR spectrum of ligand **5** in CDCl_3 .




Fig. S32. UV/Vis spectra of ligand **5** in CH_3CN . Before (pink line) and after (blue line) irradiation at 353 nm, 2.50×10^{-5} M.




Fig. S33. *Cis* to *trans* thermal isomerization kinetics of ligand **5**. Absorption change of the band 347 nm at 328 K in CH₃CN after irradiation at 353 nm (2.50×10^{-5} M).




Fig. S34. *Cis* to *trans* thermal isomerization kinetics of ligand **5**. First-order plot. k (s⁻¹) = 1.1×10^{-4} . Half-life (s) = 6500.

[Ir((ppyBr)₂Cl)₂]. Synthesis and characterization.

SYNTHESIS

To a solution of 5-bromo-2-phenylpyridine (3.00 g, 12.8 mmol) in 2-ethoxyethanol : H₂O (3:1, v/v; 60 mL) was added IrCl₃·3H₂O (1.80 g, 5.10 mmol) and the reaction mixture was heated to 120 °C for 24 h. The reaction was cooled to room temperature and 50 mL of water were added to precipitate the formed compound. The solution was gravity filtered and the solid was washed with 20 mL of hexane, 20 mL of ethanol and 50 mL of diethyl ether. The product obtained was rather insoluble in all the solvents assayed (i.e. solubility is less than 0.1 mg in 10 mL of CDCl₃), it was a light-orange powder (3.40 g, 96%). Low solubility hampered a complete NMR characterization.

Elemental Analysis: calculated for C₄₄H₂₈Br₄Cl₂Ir₂N₄: C, 38.08; H, 2.03; N, 4.04. Found: C, 38.29; H, 2.44; N, 3.92.

[Ir(ppyBr)₂(acac)]. Synthesis and characterization.**SYNTHESIS**

[Ir(ppyBr)₂Cl]₂ (150 mg, 0.11 mmol) and AgOTf (84 mg, 0.32 mmol) were dissolved in degassed acetone (8 mL) and refluxed (55 °C) under nitrogen for 2 h. The solution was cooled to room temperature and gravity-filtered to remove AgCl. The filtrate was refluxed (55 °C) under nitrogen for 1 h and added to a 1 h refluxed solution of acetylacetone (45 μL, 0.43 mmol) and triethylamine (113 μL, 0.81 mmol) dissolved in degassed acetone (4 mL). The resulting solution was refluxed overnight under nitrogen. After removing the solvent, the residue was purified by column chromatography: silica/CH₂Cl₂ (R_f = 0.8). It was obtained as a light-orange powder (106 mg, 65%)

Elemental Analysis: calculated for C₂₇H₂₁Br₂IrN₂O₂ · 2 C₃H₆O: C, 45.37; H, 3.81; N, 3.21. Found: C, 45.52; H, 4.14; N, 3.29.

Exact mass (MALDI) - m/z: 755.9575 for [M]⁺ with (¹⁹³Ir)(⁷⁹Br).

¹H NMR (300 MHz, CDCl₃): δ 8.60 (d, *J* = 1.9, 2H, C₅H₃NBr), 7.87 (dd, *J* = 8.7, 2.1, 2H, C₅H₃NBr), 7.75 (d, *J* = 8.7, 2H, C₅H₃NBr), 7.54 (dd, *J* = 7.6, 1.2, 2H, C₆H₄), 6.87 (td, 7.5, 1.3, 2H, C₆H₄), 6.77 (td, 7.4, 1.4, 2H, C₆H₄), 6.30 (d, *J* = 7.5, 2H, C₆H₄), 5.31 (s, 1H, HAcac), 1.87 (s, 6H, HAcac).

¹³C NMR (75 MHz, CDCl₃): δ 185.11 (2C, C_{quat.}), 167.58 (2C, C_{quat.}), 148.75 (2C, CH, C₅H₃NBr), 147.31 (2C, C_{quat.}), 143.49 (2C, C_{quat.}), 139.68 (2C, CH, C₅H₃NBr), 132.99 (2C, CH, C₆H₄), 129.61 (2C, CH, C₆H₄), 124.22 (2C, CH, C₆H₄), 121.10 (2C, CH, C₆H₄), 119.16 (2C, CH, C₅H₃NBr), 115.78 (2C, C_{quat.}), 100.78 (1C, CH, HAcac), 28.77 (2C, CH₃, HAcac).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 265 (4.5 · 10⁴), 312 (1.9 · 10⁴), 347 (8.6 · 10³), 380 (5.3 · 10³), 416 (3.9 · 10³), 470 (2.5 · 10³), 503 (1.0 · 10³).




Fig. S35. ¹H NMR spectrum of [Ir(ppyBr)₂(acac)] in CDCl₃, 300 MHz.




Fig. S36. ¹³C NMR spectrum of [Ir(ppyBr)₂(acac)] in CDCl₃, 75 MHz.




Fig. S37. HSQC spectrum of [Ir(ppyBr)₂(acac)] in CDCl₃.




Fig. S38. COSY spectrum of $[\text{Ir}(\text{ppyBr})_2(\text{acac})]$ in CDCl_3 .




Fig. S39. UV/Vis spectra of $[\text{Ir}(\text{ppyBr})_2(\text{acac})]$ in CH_3CN , $2.50 \cdot 10^{-5} \text{M}$.

[Ir(5)₂(acac)]. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

[Ir(ppyBr)₂(acac)] (60 mg, 0.079 mmol) was dissolved in 4 mL of degassed THF. To this mixture, 4-(phenylazo)phenyl boronic acid pinacol ester (54 mg, 0.174 mmol), Pd(PPh₃)₄ (2 mol%, 3 mg, 0.002 mmol), and Na₂CO₃ (1 M aq., 2 mL) were added successively under nitrogen. The reaction mixture was heated overnight at 80 °C with continuous stirring. The reaction was cooled to room temperature and 50 mL of water were added to precipitate the formed compound. The solution was gravity filtered and the solid was washed with hexane (20 mL). The resulting solid was purified by column chromatography (silica) eluting with dichloromethane (R_f = 0.7), obtaining 65 mg of the title compound (86% yield) as a red powder.

Elemental Analysis: calculated for C₅₁H₃₉IrN₆O₂ · 1C₆H₁₄: C, 65.43; H, 5.11; N, 8.03. Found: C, 65.10; H, 4.89; N, 7.91.

Exact mass (MALDI) - m/z: 960.2776 for [M]⁺ with (¹⁹³Ir).

¹H NMR (300 MHz, CDCl₃): δ 8.93 (d, *J* = 1.9, 2H, C₅H₃N), 8.12 – 8.08 (m, 6H), 8.00 (m, 6H), 7.84 (d, *J* = 8.6, 4H, C₆H₄ (C₁₂H₉N₂)), 7.66 (dd, *J* = 8.1, 1.2, 2H, C₆H₄ (C₁₁H₇)), 7.59 – 7.53 (m, 6H, C₆H₅), 6.91 (dt, *J* = 7.4, 1.1, 2H, C₆H₄ (C₁₁H₇)), 6.78 (dt, *J* = 7.5, 1.3, 2H, C₆H₄ (C₁₁H₇)), 6.43 (dd, *J* = 7.5, 0.8, 2H, C₆H₄ (C₁₁H₇)), 5.37 (s, 1H, HAcac), 1.89 (s, 6H, HAcac).

¹³C NMR (75 MHz, CDCl₃): δ 184.55 (2C, C_{quat.}), 167.33 (2C, C_{quat.}), 152.25 (2C, C_{quat.}), 151.88 (2C, C_{quat.}), 147.45 (2C, C_{quat.}), 145.87 (2C, CH, C₅H₃N), 143.87 (2C, C_{quat.}), 138.55 (2C, C_{quat.}), 134.76 (2C, CH, C₅H₃N), 133.04 (2C, C_{quat.}), 132.86 (2C, CH, C₆H₄ (C₁₁H₇)), 130.83 (2C, CH, C₆H₅), 128.93 (2C, CH, C₆H₄ (C₁₁H₇)), 128.72 (4C, CH, C₆H₅), 126.89 (4C, CH, C₆H₄ (C₁₂H₉N₂)), 123.76 (2C, CH, C₆H₄ (C₁₁H₇)), 123.37 (4C, CH, C₆H₄ (C₁₂H₉N₂)), 122.54, (4C, CH, C₆H₅), 120.60 (2C, CH, C₆H₄ (C₁₁H₇)), 117.97 (2C, CH, C₅H₃N), 100.34 (1C, CH, HAcac), 28.34 (2C, CH₃, HAcac).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 349 (7.9 × 10⁴), 486 (6.9 × 10³).




Fig. S40. ¹H NMR spectrum of [Ir(5)₂(acac)] in CDCl₃, 300 MHz.




Fig. S41. ^{13}C APT NMR spectrum of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$ in CDCl_3 , 75 MHz.




Fig. S42. HSQC NMR spectrum of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$ in CDCl_3 .




Fig. S43. COSY NMR spectrum of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$ in CDCl_3 .




Fig. S44. UV/Vis spectra of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$ in CH_3CN . Before (pink line) and after (blue line) irradiation at 359 nm, 2.50×10^{-5} M.




Fig. S45. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$. Absorption change of the band 349 nm at 328 K in CH_3CN after irradiation at 359 nm (2.50×10^{-5} M).




Fig. S46. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$. First-order plot. $k \text{ (s}^{-1}\text{)} = 1.1 \cdot 10^{-4}$. Half-life (s) = 6500.

[Ir(ppy)₂](1)]. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

[Ir(ppy)₂Cl]₂ (150 mg, 0.14 mmol) and AgOTf (108 mg, 0.42 mmol) were dissolved in degassed acetone (8 mL) and refluxed under nitrogen for 2 h. The solution was cooled to room temperature and gravity-filtered to remove AgCl. The filtrate was refluxed under nitrogen (55 °C) for 1 h and added to a 1 h refluxed solution of ligand **1** (205 mg, 0.56 mmol) and NEt₃ (147 µL, 1.05 mmol) in degassed acetone (4 mL). The resulting solution was refluxed overnight (55 °C) under nitrogen. After removing the solvent, the residue was purified by column chromatography: silica/CH₂Cl₂ (R_f = 0.8). It was obtained as an orange powder (120 mg, 50%).

Elemental Analysis: calculated for C₄₆H₃₄IrN₅O: C, 63.87; H, 3.96; N, 8.10. Found: C, 64.43; H, 4.23; N, 7.60.

Exact mass (MALDI) - m/z: 865.2393 for [M]⁺ with (¹⁹³Ir).

¹H NMR (500 MHz, CDCl₃): δ 8.07 (d, *J* = 5.0, 1H), 7.93 (d, *J* = 6.7, 2H), 7.90 (d, *J* = 7.7, 2H, C₂₄H₁₈N₃O), 7.86 (d, *J* = 8.5, 2H, C₂₄H₁₈N₃O), 7.78 (m, 3H), 7.69 (d, *J* = 5.9, 1H), 7.62 (m, 3H), 7.54 – 7.44 (m, 5H), 7.12 (d, *J* = 7.1, 1H), 6.93 (m, 8H), 6.70 (d, *J* = 4.5, 2H), 6.63 (d, *J* = 5.6, 1H), 6.47 (d, *J* = 7.1, 1H), 4.98 (s, 2H, CH₂).

¹³C NMR (126 MHz, CDCl₃): δ 178.38 (1C, C_{quat}), 175.06 (1C, C_{quat}), 170.59 (1C, C_{quat}), 168.12 (1C, C_{quat}), 167.98 (1C, C_{quat}), 161.55 (1C, C_{quat}), 159.14 (1C, C_{quat}), 153.35 (1C, CH), 152.91 (1C, C_{quat}), 151.34 (1C, CH), 147.88 (1C, CH), 146.87 (1C, C_{quat}), 145.49 (1C, C_{quat}), 144.84 (1C, C_{quat}), 142.32 (1C, C_{quat}), 137.24 (1C, CH), 137.22 (1C, C_{quat}), 136.62 (1C, CH), 135.61 (1C, CH), 134.15 (1C, CH), 132.81 (1C, CH), 130.59 (1C, CH), 130.36 (1C, CH), 130.07 (1C, CH), 129.76 (1C, CH), 129.13 (2C, CH, , C₁₂H₉N₂), 124.66 (2C, CH, , C₁₂H₉N₂), 124.50 (1C, CH), 124.21 (1C, CH), 124.11 (1C, CH), 122.60 (2C, CH, , C₁₂H₉N₂), 122.45 (1C, CH), 122.13 (1C, CH), 121.29 (1C, CH), 120.98 (1C, CH), 120.68 (1C, CH), 119.18 (1C, CH), 119.01 (1C, CH), 118.67 (1C, CH), 118.48 (1C, CH), 115.44 (2C, CH, C₁₂H₉N₂), 71.04 (1C, CH₂).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 345 (3.2 · 10⁴), 454 (4.0 · 10³).

Supporting Information




Fig. S47. ¹H NMR spectrum of [Ir(ppy)₂(**1**)] in CDCl₃, 500 MHz.




Fig. S48. ¹³C NMR spectrum of [Ir(ppy)₂(**1**)] in CDCl₃, 126 MHz.




Fig. S49. HSQC NMR spectrum of $[\text{Ir}(\text{ppy})_2(\mathbf{1})]$ in CDCl_3 .




Fig. S50. COSY NMR spectrum of $[\text{Ir}(\text{ppy})_2(\mathbf{1})]$ in CDCl_3 .




Fig. S51. UV/Vis spectra of [[Ir(ppy)₂(1)] in CH₃CN. Before (pink line) and after (blue line) irradiation at 349 nm, 2.50×10^{-5} M.




Fig. S52. *Cis* to *trans* thermal isomerization kinetics of [Ir(ppy)₂(1)]. Absorption change of the band 345 nm at 328 K in CH₃CN after irradiation at 349 nm (2.50×10^{-5} M).




Fig. S53. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{ppy})_2(\mathbf{1})]$. First-order plot. $k \text{ (s}^{-1}\text{)} = 1,2 \times 10^{-4}$. Half-life (s) = 5600.

[Ir(ppy)₂](2)]. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

[Ir(ppy)₂Cl]₂ (150 mg, 0.14 mmol) and AgOTf (108 mg, 0.42 mmol) were dissolved in degassed acetone (8 mL) and refluxed under nitrogen for 2 h. The solution was cooled to room temperature and gravity-filtered to remove AgCl. The filtrate was refluxed under nitrogen (55 °C) for 1 h and added to a 1 h refluxed solution of ligand **2** (196 mg, 0.56 mmol) and NEt₃ (147 µL, 1.05 mmol) in degassed acetone (4 mL). The resulting solution was refluxed overnight (55 °C) under nitrogen. After removing the solvent, the residue was purified by column chromatography: silica/CH₂Cl₂ (R_f = 0.8). It was obtained as an orange powder (100 mg, 42%).

Elemental Analysis: calculated for C₄₆H₃₄IrN₅ · C₃H₆O: C, 64.88; H, 4.44; N, 7.72. Found: C, 64.75; H, 4.21; N, 7.59.

Exact mass (MALDI) - m/z: 849.2443 for [M]⁺ with (¹⁹³Ir).

¹H NMR (300 MHz, CDCl₃): δ 8.15 (dd, *J* = 5.8, 0.9, 1H), 7.98 (dd, *J* = 8.2, 1.5, 2H, C₁₂H₉N₂), 7.87 – 7.72 (m, 7H), 7.70 – 7.63 (m, 3H), 7.61–7.43 (m, 6H), 7.10 (d, *J* = 8.4, 2H, C₁₂H₉N₂), 7.02 – 6.84 (m, 7H), 6.72 (d, *J* = 1.3, 1H), 6.72 (dddd, *J* = 7.1, 5.8, 2.4, 1.2, 1H), 6.63–6.61 (m, 1H), 6.56 (dd, *J* = 7.4, 1.3, 1H), 3.80 (s, 2H, CH₂).

¹³C NMR (75 MHz, CDCl₃): δ 177.31 (1C, C_{quat.}), 175.10 (1C, C_{quat.}), 170.52 (1C, C_{quat.}), 167.85 (1C, C_{quat.}), 166.65 (1C, C_{quat.}), 159.40 (1C, C_{quat.}), 153.17 (1C, 1CH), 152.67 (1C, C_{quat.}), 151.22 (1C, C_{quat.}), 150.95 (1C, CH), 147.77 (1C, CH), 145.18 (1C, C_{quat.}), 144.62 (1C, C_{quat.}), 142.58 (1C, C_{quat.}), 142.25 (1C, C_{quat.}), 137.89 (1C, CH), 136.75 (1C, CH), 135.40 (1C, CH), 134.63 (1C, C_{quat.}), 133.90 (1C, CH), 132.57 (1C, CH), 130.96 (1C, CH), 130.60 (1C, CH), 130.04 (1C, CH), 129.69 (1C, CH), 129.48 (1C, CH), 129.30 (2C, CH, C₁₂H₉N₂), 129.10 (2C, CH, C₁₂H₉N₂), 124.13 (1C, CH), 123.98 (1C, CH), 123.91 (1C, CH), 123.19 (2C, CH, C₁₂H₉N₂), 122.77 (2C, CH, C₁₂H₉N₂), 121.86 (1C, CH), 121.15 (1C, CH), 121.12 (1C, CH), 120.96 (1C, CH), 118.74 (1C, CH), 118.71 (1C, CH), 118.42 (1C, CH), 118.29 (1C, CH), 38.45 (1C, CH₂).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 324 (3.5 · 10⁴), 436 (5.0 · 10³).

Supporting Information




Fig. S54. ¹H NMR spectrum of [Ir(ppy)₂(**2**)] in CDCl₃, 300 MHz.




Fig. S55. ¹³C APT NMR spectrum of [Ir(ppy)₂(**2**)] in CDCl₃, 75 MHz.




Fig. S56. HSQC NMR spectrum of $[\text{Ir}(\text{ppy})_2(\mathbf{2})]$ in CDCl_3 .




Fig. S57. COSY NMR spectrum of $[\text{Ir}(\text{ppy})_2(\mathbf{2})]$ in CDCl_3 .




Fig. S58. UV/Vis spectra of $[\text{Ir}(\text{ppy})_2(\mathbf{2})]$ in CH_3CN . Before (pink line) and after (blue line) irradiation at 328 nm, 2.50×10^{-5} M.




Fig. S59. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{ppy})_2(\mathbf{2})]$. All k values were calculated from the first-order plots of absorption change of the band 324 nm at 328 K in CH_3CN after irradiation at 328 nm (2.50×10^{-5} M). *Cis* to *trans* thermal isomerization of this complex is slow, and the A_∞ (0.789) value obtained in the kinetic measure does not correspond to A_∞ value (0.826) obtained as maximum of absorbance before the photoisomerization. We have used $A_\infty = 0.826$ as maximum of absorbance corresponding to *trans* isomer. k (s^{-1}) = 0.3×10^{-4} . Half-life (s) = 21000.

[Ir(ppy)₂](3)]. Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

[Ir(ppy)₂Cl]₂ (150 mg, 0.14 mmol) and AgOTf (108 mg, 0.42 mmol) were dissolved in degassed acetone (8 mL) and refluxed under nitrogen for 2 h. The solution was cooled to room temperature and gravity-filtered to remove AgCl. The filtrate was refluxed under nitrogen (55 °C) for 1 h and added to a 1 h refluxed solution of ligand **3** (157 mg, 0.56 mmol) and NEt₃ (147 μL, 1.05 mmol) in degassed acetone (4 mL). The resulting solution was refluxed overnight (55 °C) under nitrogen. After removing the solvent, the residue was purified by column chromatography: alumina/CH₂Cl₂ (R_f = 0.7). It was obtained as an orange powder (50 mg, 23%).

Elemental Analysis: calculated for C₃₉H₃₁IrN₄O₂: C, 60.06; H, 4.01; N, 7.18. Found: C, 59.85; H, 3.84; N, 7.05.

Exact mass (MALDI) - m/z: 780.2056 for [M]⁺ with (¹⁹³Ir).

¹H NMR (300 MHz, CDCl₃): δ 8.71 (dd, *J* = 5.7, 0.7, 2H, C₁₁H₈N), 7.98 – 7.89 (m, 6H), 7.83 (ddd, *J* = 8.1, 7.4, 1.5, 2H, C₁₁H₈N), 7.62 (dd, *J* = 7.7, 1.0, 2H, C₁₁H₈N), 7.59 – 7.47 (m, 3H, C₁₂H₉N₂), 7.33 (d, *J* = 8.9, 2H, C₁₂H₉N₂), 7.27 (ddd, *J* = 7.2, 5.8, 1.4, 2H, C₁₁H₈N), 6.86 (td, *J* = 7.5, 1.2, 2H, C₁₁H₈N), 6.74 (td, *J* = 7.4, 1.3, 2H, C₁₁H₈N), 6.33 (dd, *J* = 7.6, 0.9, 2H, C₁₁H₈N), 1.61 (s, 6H, CH₃).

¹³C NMR (75 MHz, CDCl₃): δ 182.99 (2C, C_{quat.}), 168.35 (2C, C_{quat.}), 152.33 (1C, C_{quat.}), 150.74 (1C, C_{quat.}), 147.72 (2C, CH, C₁₁H₈N), 147, 63 (2C, C_{quat.}), 146.15 (1C, C_{quat.}), 144.26 (2C, C_{quat.}), 136.50 (2C, CH, C₁₁H₈N), 132.69 (4C, CH), 130.44 (1C, CH, C₁₂H₉N₂), 128.65 (2C, CH), 128.62 (2C, CH), 123.45 (2C, CH, C₁₁H₈N), 122.61 (2C, CH), 122.33 (2C, CH), 120.88 (2C, CH, C₁₁H₈N), 120.19 (2C, CH, C₁₁H₈N), 118.03 (2C, CH), 114.56 (1C, C_{quat.}), 29.18 (2C, CH₃).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 327 (3.0 · 10⁴), 455 (3.7 · 10³).




Fig. S60. ¹H NMR spectrum of [Ir(ppy)₂](**3**) in CDCl₃, 300 MHz.




Fig. S61. ¹³C NMR spectrum of [Ir(ppy)₂(3)] in CDCl₃, 75 MHz.




Fig. S62. HSQC NMR spectrum of [Ir(ppy)₂(3)] in CDCl₃.




Fig. S63. COSY NMR spectrum of $[\text{Ir}(\text{ppy})_2(\mathbf{3})]$ in CDCl_3 .




Fig. S64. UV/Vis spectra of $[\text{Ir}(\text{ppy})_2(\mathbf{3})]$ in CH_3CN . Before (pink line) and after (blue line) irradiation at 331 nm, 2.50×10^{-5} M.




Fig. S65. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{ppy})_2(\mathbf{3})]$. Absorption change of the band 327 nm at 328 K in CH_3CN after irradiation at 331 nm (2.50×10^{-5} M).




Fig. S66. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{ppy})_2(\mathbf{3})]$. First-order plot. $k \text{ (s}^{-1}\text{)} = 0.8 \times 10^{-4}$. Half-life (s) = 8300.

[Ir(Fppy)₂](1). Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

[Ir(Fppy)₂Cl]₂ (150 mg, 0.12 mmol) and AgOTf (95 mg, 0.37 mmol) were dissolved in degassed acetone (8 mL) and refluxed under nitrogen for 2 h. The solution was cooled to room temperature and gravity-filtered to remove AgCl. The filtrate was refluxed under nitrogen for 1 h and added to a 1 h refluxed solution of **1** (180 mg, 0.49 mmol) and NEt₃ (130 μ L, 0.93 mmol) in degassed acetone (4 mL). The resulting solution was refluxed overnight under nitrogen. After removing the solvent, the residue was purified by column chromatography: silica/CH₂Cl₂ (Rf = 0.8). [Ir(Fppy)₂(**1**)] was obtained as a light orange powder (92 mg, 40%).

Elemental Analysis: calculated for C₄₆H₃₀F₄IrN₅O · C₃H₆O: C, 59.15; H, 3.65; N, 7.04. Found: C, 59.17; H, 3.69; N, 6.80.

Exact mass (EI) - m/z: 938.2110 for [M+H]⁺ with (¹⁹³Ir).

¹H NMR (300 MHz, CDCl₃): δ 8.22 (t, *J* = 9.1, 2H, C₅H₄N(C₁₁H₆NF₂)), 8.04 (dd, *J* = 5.8, 1.0, 1H, C₅H₄N(C₁₁H₆NF₂)), 7.98 (d, *J* = 8.16, 1H, C₅H₄N(C₂₄H₁₈N₃O)), 7.95 – 7.88 (m, 5H), 7.81 (d, *J* = 8.1, 1H, C₆H₃), 7.70 (td, *J* = 8.0, 1.5, 1H, C₅H₄N(C₂₄H₁₈N₃O)), 7.62 – 7.48 (m, 6H), 7.18 (dd, *J* = 8.0, 1.8, 1H, C₆H₃), 7.06 – 6.97 (m, 3H), 6.93 (d, *J* = 1.5, 1H, C₆H₃), 6.77 (ddd, *J* = 6.9, 6.0, 1.3, 1H, C₅H₄N(C₁₁H₆NF₂)), 6.76 (ddd, *J* = 7.1, 5.9, 1.3, 1H, C₅H₄N(C₁₁H₆NF₂)), 6.52 – 6.42 (m, 2H, C₆H₄F₂), 6.05 (dd, *J* = 7.5, 2.3, 1H, C₆H₄F₂), 5.84 (dd, *J* = 9.2, 2.3, 1H, C₆H₄F₂), 5.06 (s, 2H, CH₂).

¹³C NMR (75 MHz, CDCl₃): δ 180.51 (1C, C_{quat}, C₁₁H₆NF₂), 175.19 (1C, C_{quat}, C₂₄H₁₈N₃O), 167.75 (1C, C_{quat}, C₂₄H₁₈N₃O), 166.89 (d, *J* = 8.1, 1C, C_{quat}, C₁₁H₆NF₂), 164.87 (dd, *J* = 10.1, *J* = 257, 1C, C_{quat}, C-F), 164.59 (d, *J* = 6.8, 1C, C_{quat}, C₁₁H₆NF₂), 163.84 (dd, *J* = 12.4, *J* = 253, 1C, C_{quat}, C-F), 162.78 (d, *J* = 6.0, 1C, C_{quat}, C₁₁H₆NF₂), 162.27 (dd, *J* = 10.9, *J* = 262, 1C, C_{quat}, C-F), 161.66 (dd, *J* = 13.1, *J* = 258, 1C, C_{quat}, C-F), 161.26 (1C, C_{quat}, C₂₄H₁₈N₃O), 153.10 (1C, CH, C₅H₄N(C₁₁H₆NF₂)), 152.82 (1C, C_{quat}, C₂₄H₁₈N₃O), 150.90 (1C, CH, C₅H₄N(C₂₄H₁₈N₃O)), 147.68 (1C, CH), 146.88 (1C, C_{quat}, C₂₄H₁₈N₃O), 144.89 (1C, C_{quat}, C₂₄H₁₈N₃O), 137.76 (1C, C_{quat}, C₂₄H₁₈N₃O), 137.13 (1C, CH, C₅H₄N(C₂₄H₁₈N₃O)), 136.55 (1C, CH, C₆H₃), 136.45 (1C, CH), 135.22 (1C, CH), 130.27 (1C, CH, C₆H₃), 129.01 (2C, CH, C₁₂H₉N₂), 127.88 (1C, C_{quat}, C₁₁H₆NF₂), 126.41 (1C, C_{quat}, C₁₁H₆NF₂), 124.63 (1C, CH, C₆H₃), 124.57 (2C, CH, C₁₂H₉N₂), 122.80 (d, *J* = 21.3, 1C, CH, C₅H₄N(C₁₁H₆NF₂)), 122.66 (1C, CH, C₅H₄N(C₂₄H₁₈N₃O)), 122.58 (d, *J* = 19.0, 1C, CH, C₅H₄N(C₁₁H₆NF₂)), 122.51 (2C, CH, C₁₂H₉N₂), 122.29 (1C, CH, C₅H₄N(C₁₁H₆NF₂)), 121.48 (1C, CH, C₅H₄N(C₁₁H₆NF₂)), 121.17 (1C, CH, C₆H₃), 119.43 (1C, CH, C₅H₄N(C₂₄H₁₈N₃O)), 115.32 (2C, CH, C₁₂H₉N₂), 113.71 (d, *J* = 14.1, 1C, CH, C₆H₄F₂), 111.93 (d, *J* = 16.3, 1C, CH, C₆H₄F₂), 97.42 (pst, *J* = 27.2, 1C, CH, C₆H₄F₂), 95.47 (pst, *J* = 27.1, 1C, CH, C₆H₄F₂), 70.67 (1C, CH₂).

UV/Vis (CH₃CN, λ , nm (ϵ , L mol⁻¹ cm⁻¹)): 346 (3.1 $\times$ 10⁴), 436 (4.0 $\times$ 10³).

Supporting Information




Fig. S67. ¹H NMR spectrum of [Ir(Fppy)₂(**1**)] in CDCl₃, 300 MHz.




Fig. S68. ¹³C NMR spectrum of [Ir(Fppy)₂(**1**)] in CDCl₃, 75 MHz.




Fig. S69. HSQC NMR spectrum of $[\text{Ir}(\text{Fppy})_2(\mathbf{1})]$ in CDCl_3 .




Fig. S70. COSY NMR spectrum of $[\text{Ir}(\text{Fppy})_2(\mathbf{1})]$ in CDCl_3 .




Fig. S71. UV/Vis spectra of $[\text{Ir}(\text{Fppy})_2(\mathbf{1})]$ in CH_3CN . Before (pink line) and after (blue line) irradiation at 349 nm, 2.50×10^{-5} M.




Fig. S72. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{Fppy})_2(\mathbf{1})]$. Absorption change of the band 346 nm at 328 K in CH_3CN after irradiation at 349 nm (2.50×10^{-5} M).




Fig. S73. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{Fppy})_2(\mathbf{1})]$. First-order plot. $k \text{ (s}^{-1}\text{)} = 1.1 \times 10^{-4}$. Half-life (s) = 6300.

[Ir(Brppy)₂](1). Synthesis, characterization and photoisomerization studies.**SYNTHESIS**

[Ir(Brppy)₂Cl]₂ (150 mg, 0.11 mmol) and AgOTf (84 mg, 0.32 mmol) were dissolved in degassed acetone (8 mL) and refluxed under nitrogen for 2 h. The solution was cooled to room temperature and gravity-filtered to remove AgCl. The filtrate was refluxed under nitrogen for 1 h and added to a 1 h refluxed solution of **1** (158 mg, 0.43 mmol) and triethylamine (113 μ L, 0.81 mmol) dissolved in degassed acetone (4 mL). The resulting solution was refluxed overnight under nitrogen. After removing the solvent, the residue was purified by column chromatography: silica/CH₂Cl₂ (R_f = 0.9). It was obtained as an orange powder (74 mg, 35%).

Elemental Analysis: calculated for C₄₆H₃₂Br₂IrN₅O · C₃H₆O: C, 54.45; H, 3.54; N, 6.48. Found: C, 54.24; H, 3.65; N, 6.17.

Exact mass (MALDI) - m/z: 1021.0578 for [M]⁺ with (¹⁹³Ir)(⁷⁹Br).

¹H NMR (300 MHz, CDCl₃): δ 7.99-7.88 (m, 7H), 7.81-7.74 (m, 3H), 7.67 (td, *J* = 7.7, 1.5, 1H), 7.60 – 7.47 (m, 8H), 7.18-7.09 (m, 3H), 7.03 – 6.95 (m, 3H), 6.93 (d, *J* = 1.1, 1H, C₆H₃), 6.80 – 6.71 (m, 2H), 6.69 (d, *J* = 2.0, 1H, C₆H₄Br), 6.50 (d, *J* = 1.9, 1H, C₆H₄Br), 5.05 (d, *J* = 2.2, 2H, CH₂).

¹³C NMR (75 MHz, CDCl₃): δ 177.52 (1C, C_{quat.}), 175.78 (1C, C_{quat.}), 169.23 (1C, C_{quat.}), 167.86 (1C, C_{quat.}), 166.77 (1C, C_{quat.}), 161.30 (1C, C_{quat.}), 160.77 (1C, C_{quat.}), 153.10 (1C, CH), 152.84 (1C, C_{quat.}), 151.16 (1C, CH), 147.76 (1C, CH), 146.87 (1C, C_{quat.}), 145.05 (1C, C_{quat.}), 143.56 (1C, C_{quat.}), 141.41 (1C, C_{quat.}), 137.55 (1C, C_{quat.}), 136.90 (1C, CH), 136.69 (1C, CH, C₆H₃), 136.02 (1C, CH), 135.12 (1C, CH, C₆H₄Br), 134.67 (1C, CH), 132.79 (1C, CH, C₆H₄Br), 130.26 (1C, CH), 129.02 (2C, CH, C₁₂H₉N₂), 126.75 (1C, C_{quat.}), 125.84 (1C, CH), 125.53 (1C, CH), 125.19 (1C, C_{quat.}), 124.57 (2C, CH, C₁₂H₉N₂), 124.51 (1C, CH), 124.31 (1C, CH), 122.63 (1C, CH), 122.51 (3C, 2CH C₁₂H₉N₂ + CH), 122.39 (1C, CH), 121.80 (1C, CH), 120.95 (1C, CH), 119.24 (1C, CH), 118.99 (1C, CH), 118.79 (1C, CH), 115.46 (2C, CH, C₁₂H₉N₂), 70.70 (1C, CH₂).

UV/Vis (CH₃CN, λ , nm (ϵ , L mol⁻¹ cm⁻¹)): 343(2.8 · 10⁴), 448 (4.0 · 10³).




Fig. S74. ¹H NMR spectrum of [Ir(Brppy)₂](**1**) in CDCl₃, 300 MHz.




Fig. S75. ^{13}C NMR spectrum of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$ in CDCl_3 , 75 MHz.




Fig. S76. HSQC NMR spectrum of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$ in CDCl_3 .




Fig. S77. COSY NMR spectrum of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$ in CDCl_3 .




Fig. S78. UV/Vis spectra of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$ in CH_3CN . Before (pink line) and after (blue line) irradiation at 349 nm, 2.50×10^{-5} M.




Fig. S79. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$. Absorption change of the band 343 nm at 328 K in CH_3CN after irradiation at 349 nm (2.50×10^{-5} M).




Fig. S80. *Cis* to *trans* thermal isomerization kinetics of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$. First-order plot. k (s^{-1}) = 1.2×10^{-4} . Half-life (s) = 5800.

[Ir(4)₂(1)]. Synthesis and characterization.**SYNTHESIS**

[Ir(Brppy)₂(1)] (60 mg, 0.058 mmol) was dissolved in 4 mL of degassed THF. To this mixture, 4-(phenylazo)phenyl boronic acid pinacol ester (40 mg, 0.129 mmol), Pd(PPh₃)₄ (2 mol%, 3 mg, 0.002 mmol), and Na₂CO₃ (1 M aq., 2 mL) were added successively under nitrogen. The reaction mixture was heated overnight at 80 °C with continuous stirring. The reaction was cooled to room temperature and 50 mL of water were added to precipitate the formed compound. The solution was gravity filtered and the solid was washed with hexane (20 mL) and dichloromethane (10 mL). The compound was obtained as a dark-orange powder (70 mg, 92%), rather insoluble in all the solvents assayed (i.e. solubility is less than 0.8 mg in 10 mL of CDCl₃). Low solubility hampered a complete NMR characterization.

Elemental Analysis: calculated for C₇₀H₅₀IrN₉O · 2CH₂Cl₂ · 1C₆H₁₄: C, 63.24; H, 4.63; N, 8.51. Found: C, 63.34; H, 4.09; N, 8.55.

Exact mass (MALDI) - m/z: 1225.3766 for [M]⁺ with (¹⁹³Ir).

UV/Vis (CH₃CN, λ, nm (ε, L mol⁻¹ cm⁻¹)): 351 (6.5 · 10⁴), 465 (6.6 · 10³).




Fig. S81. UV/Vis spectra of [Ir(4)₂(1)] in CH₂Cl₂. Before (pink line) and after (blue line) irradiation at 354 nm, 0.90 × 10⁻⁵ M.




Fig. S82. ^1H -NMR spectra of ligand **1** in CDCl_3 , 300 MHz. Before (red line) and after (blue line) irradiation at 365 nm, 2.50×10^{-3} M.




Fig. S83. ^1H -NMR spectra of ligand **2** in CDCl_3 , 300 MHz. Before (red line) and after (green line) irradiation at 365 nm, 2.50×10^{-3} M. After heating overnight at 55°C (blue line).




Fig. S84. ^1H -NMR spectra of ligand **3** in CDCl_3 , 300 MHz. Before (red line) and after (green line) irradiation at 365nm, $2.50 \cdot 10^{-3}$ M. After heating overnight at 55 °C (blue line).




Fig. S85. ^1H -NMR spectra of ligand **4** in CDCl_3 , 300 MHz. Before (red line) and after (blue line) irradiation at 365nm, 2.50×10^{-3} M.




Fig. S86. ^1H -NMR spectra of ligand **5** in CDCl_3 , 300 MHz. Before (red line) and after (blue line) irradiation at 365nm, 2.50×10^{-3} M.




Fig. S87. ^1H -NMR spectra of $[\text{Ir}(\mathbf{4})_2(\text{acac})]$ in CDCl_3 , 300 MHz. Before (red line) and after (blue line) irradiation at 365nm, 2.50×10^{-3} M.




Fig. S88. ^1H -NMR spectra of $[\text{Ir}(\mathbf{5})_2(\text{acac})]$ in CDCl_3 , 300 MHz. Before (red line) and after (blue line) irradiation at 365 nm, 2.50×10^{-3} M.




Fig. S89. ^1H -NMR spectra of $[\text{Ir}(\text{ppy})_2(\mathbf{2})]$ in CDCl_3 , 300 MHz. Before (red line) and after (blue line) irradiation at 365 nm, 2.50×10^{-3} M.

Chemical structure of compound 10 is shown in the top left. The ^1H NMR spectrum (CDCl₃) is displayed below, showing two traces (green and red) and integration values (61% and 39%). The x-axis is labeled f_1 (ppm) and ranges from 9.2 to 4.2.

S60




Fig. S92. ^1H -NMR spectra of $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$ in CDCl_3 , 300 MHz.. Before (red line) and after (blue line) irradiation at 365nm, 2.50×10^{-3} M.




Fig. S93. ^1H -NMR spectra of $[\text{Ir}(\text{ppy})_2(\mathbf{3})]$ in CDCl_3 , 300 MHz.. Before (red line) and after (blue line) irradiation at 365nm, 2.50×10^{-3} M.




Figure S94. Cyclic voltammograms (10⁻³ M, dry DMF) of [Ir(ppy)₂(1)], [Ir(Fppy)₂(1)] and [Ir(Brppy)₂(1)] containing 0.1 M TBAPF₆ as the supporting electrolyte, scan rate of 100 mV s⁻¹.




Figure S95. Cyclic voltammograms (10⁻³ M, dry DMF) of [Ir(ppy)₂(4)] and [Ir(Fppy)₂(4)] containing 0.1 M TBAPF₆ as the supporting electrolyte, scan rate of 100 mV s⁻¹.




Figure S96. Cyclic voltammograms (10^{-3} M, dry DMF) of [Ir(4)₂(acac)] and [Ir(5)₂(acac)] containing 0.1 M TBAPF₆ as the supporting electrolyte, scan rate of 100 mV s^{-1} .




Figure S97. Cyclic voltammograms (10^{-3} M, dry DMF) of [Ir(ppy)₂(2)] containing 0.1 M TBAPF₆ as the supporting electrolyte, scan rate of 100 mV s^{-1} .




Figure S98. Cyclic voltammograms (10^{-3} M, dry DMF) of $[\text{Ir}(\text{ppy})_2(\mathbf{3})]$ containing 0.1 M TBAPF_6 as the supporting electrolyte, scan rate of 100 mV s^{-1} .




Figure S99. $-\text{OCH}_2-$ signal of the ^1H -NMR spectra of compounds $[\text{Ir}(\text{Fppy})_2(\mathbf{1})]$ and $[\text{Ir}(\text{Brppy})_2(\mathbf{1})]$. Top (experimental) bottom (simulated). Chemical shift and coupling constants used for the simulation are presented in the table.